Senetek, Nastech strike deals for RNAi technology

Senetek has struck a deal to acquire RNAi technology for brain tumors from the Institute of Bioorganic Chemistry of the Polish Academy of Sciences. The deal includes the rights to three anti-aging compounds for skin. The brain tumor technology is designed to inhibit the production of tenascin-C, which is linked to malignancy. "This new technology works not only to prolong the survival of patients suffering from brain tumors, but possibly to cure them as well," said CEO Frank Massino. RNAi technology has turned red-hot in the wake of this year's Nobel Prize for the field's pioneers.

- check out the UPI report on Senetek

ALSO: Nastech struck a licensing deal with City of Hope for RNAi technology. Release

Related Articles:
Calando inks RNAi pact with Alnylam. Report
Sirna posts positive data on RNAi therapy. Report
Nastech to push ahead with obesity spray trial. Report